AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
3.150
-0.030 (-0.94%)
At close: Dec 23, 2025, 4:00 PM EST
3.150
0.00 (0.00%)
After-hours: Dec 23, 2025, 4:00 PM EST
AC Immune Revenue
AC Immune had revenue of 939.00K CHF in the quarter ending September 30, 2025, a decrease of -96.32%. This brings the company's revenue in the last twelve months to 4.37M, down -89.33% year-over-year. In the year 2024, AC Immune had annual revenue of 27.31M with 84.51% growth.
Revenue (ttm)
4.37M CHF
Revenue Growth
-89.33%
P/S Ratio
58.28
Revenue / Employee
25,419 CHF
Employees
172
Market Cap
311.67M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
| Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
| Dec 31, 2022 | 3.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
| Dec 31, 2019 | 110.46M | 103.54M | 1,498.03% |
| Dec 31, 2018 | 6.91M | -13.34M | -65.88% |
| Dec 31, 2017 | 20.26M | -2.96M | -12.75% |
| Dec 31, 2016 | 23.21M | -15.88M | -40.61% |
| Dec 31, 2015 | 39.09M | 8.82M | 29.14% |
| Dec 31, 2014 | 30.27M | 21.63M | 250.46% |
| Dec 31, 2013 | 8.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ACIU News
- 8 days ago - AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD - Seeking Alpha
- 12 days ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 12 days ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 7 weeks ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire
- 5 months ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 8 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 9 months ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire